Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-04-29
2008-04-29
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C530S387100, C530S387300, C530S388100
Reexamination Certificate
active
11429362
ABSTRACT:
A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
REFERENCES:
patent: 4490473 (1984-12-01), Brunhouse
patent: 4752601 (1988-06-01), Hahn
patent: 5204244 (1993-04-01), Fell et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5419904 (1995-05-01), Irie
patent: 5576184 (1996-11-01), Better et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6491916 (2002-12-01), Bluestone et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6676927 (2004-01-01), Ravetch
patent: 6706265 (2004-03-01), Bolt et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 7122637 (2006-10-01), Presta
patent: 7183387 (2007-02-01), Presta
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0098193 (2002-07-01), Ward
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2003/0166868 (2003-09-01), Presta et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0191244 (2004-09-01), Presta
patent: 2004/0228856 (2004-11-01), Presta
patent: 2005/0118174 (2005-06-01), Presta
patent: 2005/0233382 (2005-10-01), Presta
patent: 2006/0194291 (2006-08-01), Presta
patent: 2006/0194954 (2006-08-01), Idusogie et al.
patent: 2006/0194957 (2006-08-01), Presta
patent: 2007/0009523 (2007-01-01), Presta
patent: WO 88/07089 (1988-09-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/060919 (2002-08-01), None
Allan and Isliker, “Studies on the complement-binding site of rabbit immunoglobulin G-I. Modification of tryptophan residues and their role in anticomplementary activity of rabbit IgG”Immunochemistry11(4):175-180 (Apr. 1974).
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”Molecular Immunology30(1):105-108 (Jan. 1993).
Antibodies. A Laboratory Manual, Harlow and Lane, New York:Cold Spring Harbor Laboratory pp. 321 (1988).
Armour et al., “Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities”European Journal of Immunolgy. 29(8):2613-2624 (1999).
Bloom et al., “Intrachain disulfide bond in the core hinge region of human IgG4”Protein Science6:407-415 (1997).
Bolland et al., “SHIP modulates immune receptor responses by regulating membrane association of Btk”Immunity8(4):509-516 (Apr. 1998).
Bredius et al., “Role of neutrophil FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes”Immunology83(4):624-630 (Dec. 1994).
Brekke et al., “Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated Cell Lysis and Phagocytosis.”European Journal of Immunology24(10):2542-2547 (Oct. 1994).
Burmeister et al., “Crystal Structure of the Complex of Rat Neonatal Fc Receptor with Fc.”Nature372(6504):379-383 (Nov. 24, 1994).
Burton and Woof, “Human Antibody Effector Function”Advance in Immunology51:1-84 (1992).
Burton et al., “Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)”Molecular Immunology25(11):1175-1181 (1988).
Burton et al., “The C1q Receptor Site on Immunoglobulin G.”Nature288(5798):338-344 (Nov. 27, 1980).
Burton, D.R., “Immunoglobulin G: Functional Sites”Molecular Immunology22(3):161-206 (1985).
Canfield and Morrison, “The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and is Modulated by the Hinge Region.”J. Experimental Medicine173(6):1483-1491 (Jun. 1, 1991).
Capel et al., “Heterogeneity of Human IgG Fc Receptors”Immunomethods4:25-34 (1994).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy”Nature337:525-531 (Feb. 9, 1989).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10):4285-4289 (May 1992).
Chappel et al., “Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody”Journal of Biological Chemistry268:25124-25131 (1993).
Chappel et al., “Identification of the Fcγ Receptor Class I Binding Site in Human IgG Through the use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies.”Proc. Natl. Acad. Sci. USA88(20):9036-9040 . (Oct. 15, 1991).
Clynes and Ravetch. “Cytotoxic antibodies trigger inflammation through Fc receptors”Immunity3(1):21-26 (Jul. 1995).
Clynes et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma”Proc. Natl. Acad. Sci. USA95(2):652-656 (Jan. 1998).
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors”Journal of Experimental Medicine189(1):179-185 (Jan. 4, 1999).
Clynes et al., “Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis”Science279(5353):1052-1054 (Feb. 13, 1998).
Cosimi, A.B., “Clinical Development of ORTHOCLONE OKT3”Transplantation Proceedings(Suppl 1) XIX(2):7-16 (Apr. 1987).
Daeron, M., “Fc Receptor Biology”Annual Review of Immunology15:203-234 (1997).
de Haas et al., “Fcγ Receptors of Phagocytes”J. of Laboratory Clinical Medicine126:330-341 (Oct. 1995).
Deisenhofer, J, “Crystallographic Refinement and Atomic Models of a Human Fc Fragment and Its Complex with Fragment B of Protein A fromStaphylococcus aureusat 2.9- and 2.8-A Resolution”Biochemistry20(9):2361-2370 (1981).
Duncan and Winter, “The Binding Site for C1q on IgG.”Nature332:738-740 (Apr. 21, 1988).
Duncan et al., “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG.”Nature332:563-564 (Apr. 7, 1988).
Fridman, W., “Fc receptors and immunoglobulin binding factors”FASEB Journal5(12):2684-2690 (Sep. 1991).
Fundamental Immunology, Paul, W. E., 2nd edition, New York:Raven Press pp. 60 and 61 (1989).
Gazzano-Santoro et al., “A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody”Journal of Immunological Methods. 202(2):163-171 (Mar. 28, 1997).
Gergely et al., “Fc Receptors on Lymphocytes and K Cells.”Biochemical Society Transactions12(5):739-743 (Oct. 1984).
Ghebrehiwet et al., “Isolation, cDNA cloning, and overexpressi
Idusogie Esohe Ekinaduese
Mulkerrin Michael George
Presta Leonard G.
Crowder Chun
Genentech Inc.
Haddad Maher M.
Lee Wendy M.
LandOfFree
Polypeptide variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3920252